ZNF791

Across TCGA pan-cancer cohorts, ZNF791 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF791 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZNF791 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ZNF791 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LGG show a favorable association.

BLCA, LUSC, and SKCM are the cancer types where ZNF791 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.406	.025	11	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	OS	Median	All	1.000	0.413	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF791–BLCA (OS)

Open the BLCA breakdown →